Skip to main content
SpringerLink
Log in

Cost Saving of 5-day Therapy with Cefpodoxime Proxetil versus Standard 10-day β-Lactam Therapy for Recurrent Pharyngotonsillitis in Adults

A Prospective General Practice Study

  • Original Research Article
  • Cefpodoxime Proxetil in Tonsillitis
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

A prospective economic evaluation was undertaken as part of a randomised clinical trial conducted in French general practice. Its aim was to compare the costs and therapeutic outcomes of a 5-day course of cefpodoxime proxetil 100mg twice daily with 10-day courses of phenoxymethylpenicillin (penicillin V) 1 MIU 3 times daily and amoxicillin-clavulanic acid 500/l25mg 3 times daily for the treatment of recurrent pharyngotonsillitis in 575 adults.

Over the 6-month study period, the total cost to society per patient treated with cefpodoxime proxetil was 123 French francs (FF; 1993 values) lower than that for patients treated with phenoxymethylpenicillin and FF227 lower than that for patients treated with amoxicillin-clavulanic acido This cost saving was primarily attributable to a lower initial drug acquisition cost, and a reduction in the cost associated with lost productivity and general practitioner consultations. Furthermore, as a consequence of a lower relapse rate, the cost-saving ratio for cefpodoxime proxetil, expressed as FF per month free of recurrence, was FF50 less than for phenoxymethylpenicillin and FF60 less than for amoxicillin-clavulanic acido

Thus, a 5-day course of cefpodoxime proxetil is likely to be less costly for treatment of pharyngotonsillitis in the general practice setting than standard IO-day courses of phenoxymethylpenicillin and amoxicillin-clavulanic acido

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Pichichero ME. Group A streptococcal tonsillopharyngitis: cost–effective diagnosis and treatment. Ann Emerg Med 1995; 25: 390–403

    Article  PubMed  CAS  Google Scholar 

  2. ReynoIds JEF, editor. MartindaIe: the extra pharmacopoeia. 30th rev. London: The Pharmaceutical Press, 1993

  3. Schwartz R, Wientzen R, Pedaeira F, et al. Penicillin V for group A streptococcal pharyngotonsillitis. JAMA 1981; 246: 1790–5

    Article  PubMed  CAS  Google Scholar 

  4. Gerber MA, Randolph MF, Chanatry J, et al. Five vs ten days of penicillin V therapy for streptococcal pharyngitis. Am JDis Child 1987; 141: 224–7

    CAS  Google Scholar 

  5. Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician 1990; 42: 1567–76

    PubMed  CAS  Google Scholar 

  6. Kaplan EL, Johnson DR. Eradication ofgroup Astreptococci from the upper respiratory tract by amoxicillin with clavulanate afteroral penicillin V treatment failure. J Pediatr 1988; 113: 400–3

    Article  PubMed  CAS  Google Scholar 

  7. Brook I. Treatment of patients with acute recurrent tonsillitis due to group A beta–hemoIytic streptococci: a prospectiverandomised study comparing penicillin and amoxicillinlclavulanate potassium. J Antimicrob Chemother 1989; 24: 227–33

    Article  PubMed  CAS  Google Scholar 

  8. Frampton JE, Brogden RN, Langtry HD, et al. Cefpodoxime proxetil: a review of its antibacterial activity, pharmacokineticproperties and therapeutic potential. Drugs 1992; 44: 889–917

    Article  PubMed  CAS  Google Scholar 

  9. Brown RJ, Batts DH, Hughes GS, et al. Comparison of oral cefpodoxime proxetil and penicillin V potassium in the treatmentof Group A streptococcal pharyngitis/tonsillitis. ClinTher 1991; 13: 579–88

    PubMed  CAS  Google Scholar 

  10. Portier H, Waldner-Combernoux A, Clarysse L, et al. Cefpodoxime proxetil vs amoxicillin in the treatment of pharyngitisltonsillitis in adult out–patients [poster no. 33]. Intemational Congressfor Infectious Diseases: 1990 July 15-19; Montreal: 110–2

    Google Scholar 

  11. Portier H, Chavanet P, Waldner-Combernoux A, et al. Five versus ten days’ treatment of streptococcal pharyngotonsillitis: a randomizedcontrolled trial comparing cefpodoxime proxetil andphenoxymethyI penicillin. Scand J Infect Dis 1994; 26: 59–66

    Article  PubMed  CAS  Google Scholar 

  12. Portier H, Chavanet P, Waldner-Cohen R, et al. Five days’ cefpodoxime proxetil (RU 51807) vs ten days’ penicillin Vfor streptococcal pharyngitis/tonsillitis in chiIdren [abstractno. 1674]. Interscience Conference on Antimicrobial Agentsand Chemotherapy; 1994 Oct 11-14; Anaheim (CA): 390

    Google Scholar 

  13. Portier H, Weber P, Gehanno H, et al. Recurrent tonsillitis in adult patients: a comparative clinical evaluation of cefpodoximeproxetil 5 days versus two other betalactam therapieslO days [abstract no. 1230]. International Congress for Infectious Diseases; 1994 Apr 26–30; Prague

    Google Scholar 

  14. Data on file, Roussel Vclaf, 1993

  15. VIDAL 1993. Paris: Edition du Vidal, 1993

  16. Journal officiel de la République Franςaise 1992; 153: 8854

  17. VCANSS. Nomenclature Générale des Actes Professionnels et des Actes de Biologie Médicale. Vnion des Caisses Nationalesde Sécurité Sociale, 1990: 1–105

    Google Scholar 

  18. CNAMTS. Statistiques Mensuelles; résultats à fin Novembre 1992. Caisse Nationale d’Assurance Maladie des TravailleursSalariés, 1990: 25

    Google Scholar 

  19. Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89

    Article  PubMed  CAS  Google Scholar 

  20. Pelc A, Montron A, Ichou F, et al. Cefpodoxime proxetil5 days versus penicillin V lO days in adult patients with GABS pharyngitis:a cost–effectiveness analysis [poster]. The 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2; Stockholm: 387

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Economics Department, IMS International, IMS, 325–345 Avenue Georges Clémenceau, T5A 30001, 92882 Nanterre CTC Cedex 9, Montrouge, France

    Alain Pelc

  2. Service des Maladies Infectieuses, Hopital du Bocage, Dijon, France

    Henri Portier

  3. Service d’ ORL, Hopital Bichat Claude Bernard, Paris, France

    Pierre Gehanno

  4. Roussel UCLAF, Romainville, France

    Sylvie Fiessinger

  5. Laboratoires Diamant, Paris–La–Défense, France

    Françoise Ichou

Authors
  1. Alain Pelc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henri Portier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Gehanno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvie Fiessinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Françoise Ichou
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pelc, A., Portier, H., Gehanno, P. et al. Cost Saving of 5-day Therapy with Cefpodoxime Proxetil versus Standard 10-day β-Lactam Therapy for Recurrent Pharyngotonsillitis in Adults. Pharmacoeconomics 10, 239–250 (1996). https://doi.org/10.2165/00019053-199610030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610030-00005

Keywords

Search

Navigation